Samuel Taylor, PhD
Postdoctoral Fellow at Albert Einstein College of Medicine
2018 NYSCF – Druckenmiller Fellow
PhD, University of Western Australia, Perth, Australia
Dr. Taylor is interested in treating acute myeloid leukemia (AML), a type of blood cancer, by specifically targeting AML stem cells, in turn eliminating the source of the cancer and the possibility for relapse after treatment. His research has shown that more than 50% of AML patients display a decreased expression of a transcription factor called PU.1 – transcription factors control the expression of genetic information – but never a total absence of expression, as this would cause the stem cells to die. Moving forward, he will test the further inhibition of PU.1 with the hope of eliminating AML stem cells, and ultimately, stopping tumor production at the source.